SecBot SecBot

PTGX drug pipeline

$124.83
−4.7% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±0.9%
1-day, median of 7 events
IV rank
No data
No current options data
Rated drugs
5
5 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially launched in the US (March 2026), EU (September 2026), and UK (October 2026).

ICOTYDE icotrokinra Updated Nov 9

What to watch

ICOTYDE is already approved and generating revenue. The next major catalyst would be a regulatory filing for psoriatic arthritis (Phase 3 data just presented at ACR Nov 2026), but no submission or PDUFA date has been announced yet. Watch for J&J's filing plans and quarterly royalty revenue growth as the commercial launch ramps.

Bull case
  • ICOTYDE is the first and only FDA-approved oral peptide targeting IL-23R for plaque psoriasis, offering a novel once-daily pill alternative to injectable biologics in a multi-billion-dollar market.
  • BofA sees peak sales potential of $4.5 billion for ICOTYDE, suggesting substantial royalty revenue upside for Protagonist if J&J executes on the commercial launch.
  • Phase 3 psoriatic arthritis data (presented Nov 2026 at ACR) showed 58% ACR20 vs 41% placebo, opening a large label-expansion opportunity that could significantly increase the addressable market.
Bear case
  • Insider selling: CFO Ali Asif sold $6.5M+ in stock on Sept 30, 2026, and CEO Dinesh Patel sold over $20M in stock across multiple transactions in Aug-Sep 2026 (all under 10b5-1 plans but still notable).
  • Several large institutional holders exited or trimmed positions in Q2 2026, including Citadel (exit), Adage Capital (exit), Rubric Capital (exit), and Marshall Wace (near-exit), suggesting profit-taking after the approval-driven rally.
  • Competition in the oral psoriasis market is intensifying: Sotyktu (deucravacitinib, BMS) is already on the market, and Alumis is advancing envudeucitinib (TYK2 inhibitor) through Phase 3 with positive data.
● neutral
Impact
PhasePreclinical (development candidate nominated)
Time to marketYears away. PN-477 is preclinical with no IND filed as of November 2026. If development proceeds, Phase 1 initiation would be at least 12-18 months out, and potential approval (if successful) would be 5+ years away.

PN-477 Updated Nov 9

What to watch

PN-477 is a preclinical-stage asset with no IND filing or clinical trial start announced as of November 2026. Watch for IND filing or Phase 1 initiation updates, but the stock's near-term value is driven by commercial execution of ICOTYDE and MIMRYLO, not this early-stage candidate.

Bull case
  • PN-477 is a triple GLP-1/GIP/GCG receptor agonist with both oral and subcutaneous routes, potentially offering best-in-class weight loss and patient convenience if preclinical promise translates to humans.
  • Protagonist has deep expertise in oral peptide discovery, having already brought two drugs to FDA approval (ICOTYDE, MIMRYLO), which de-risks the platform.
  • The obesity market is massive (projected $100B+ annually), and an oral triple agonist could capture significant share if it matches injectable efficacy.
Bear case
  • PN-477 is preclinical and years away from any revenue, with no guarantee it will ever reach clinical trials or prove safe/efficacious in humans.
  • The obesity market is intensely competitive with established players Novo Nordisk (Wegovy/Ozempic), Eli Lilly (Zepbound/Mounjaro), and many other triple agonists in development, making differentiation difficult.
  • Protagonist's focus is currently on commercializing ICOTYDE and MIMRYLO and advancing PN-881 (Phase 2b), so PN-477 may receive limited resources near-term.
● neutral
Impact
PhasePhase 1 completed; Phase 2b planned
Time to marketIf Phase 2b initiates in 2027 and proceeds smoothly, a potential approval would likely be several years away (estimated 2029-2031), assuming positive data across Phase 2b and Phase 3 trials.

PN-881 Updated Nov 9

What to watch

Watch for the initiation of the Phase 2b psoriasis program, which the company has guided as planned. Positive Phase 1 safety/tolerability data could support a rapid move into Phase 2b. As a wholly-owned asset at a now-profitable company with two approved drugs, PN-881 represents pipeline upside but is not a near-term binary catalyst.

Bull case
  • PN-881 is a wholly-owned oral peptide IL-17 antagonist with preclinical data showing potency comparable to bimekizumab and roughly 70-100 fold greater than secukinumab, suggesting best-in-class potential.
  • Protagonist has a proven oral peptide platform (icotrokinra/ICOTYDE already FDA-approved), de-risking the technology for PN-881.
  • The company is now profitable with $220M net income in Q3 2026 and has strong cash flow from two approved drugs (ICOTYDE and rusfertide), providing ample funding for PN-881 development without dilution.
Bear case
  • PN-881 is still in early clinical development (Phase 1 completed, Phase 2b not yet initiated) and faces a long, expensive development path before any potential approval.
  • The IL-17 inhibitor market is crowded with approved injectable biologics (Cosentyx, Taltz, Bimzelx) from large pharma; an oral peptide will need to demonstrate a clear efficacy/safety advantage to capture share.
  • CEO Dinesh Patel sold shares worth approximately $17.5M in September 2026 under a 10b5-1 plan, and CFO Ali Asif also sold shares, which may signal insider caution about near-term valuation.
● neutral
Impact
PhasePreclinical
Time to marketAt preclinical stage, typical timelines to potential approval are 5-8 years, assuming successful completion of IND-enabling studies, Phase 1-3 trials, and regulatory review. No IND filing date has been announced.

PN-458 Updated Nov 9

What to watch

PN-458 is too early-stage to drive any near-term stock movement for PTGX. Investors should focus on the company's nearer-term catalysts: PN-881 Phase 2b initiation in early Q1 2027, commercial execution of ICOTYDE (partnered with J&J) and MIMRYLO (partnered with Takeda), and the pace of the $300M buyback. Any meaningful PN-458 data or IND announcement would be a positive surprise but is not on the near-term calendar.

Bull case
  • PN-458 targets the massive GLP-1/GIP dual agonist market (dominated by tirzepatide, which generated over $20B in 2025 sales), and an oral formulation could differentiate it from injectable-only competitors.
  • Protagonist has a proven peptide-engineering platform that already delivered two FDA-approved drugs (ICOTYDE/icotrokinra and MIMRYLO/rusfertide), lending credibility to its preclinical pipeline.
  • The company has a strong balance sheet ($834.6M cash as of Q3 2026) and is now cash-flow positive, meaning PN-458 development does not depend on dilutive financing.
Bear case
  • PN-458 is at the earliest preclinical stage with no disclosed IND timeline, no in vivo data, and no assurance it will ever enter clinical trials.
  • The GLP-1/GIP dual agonist space is intensely competitive, with tirzepatide (Eli Lilly), survodutide (Boehringer Ingelheim/Zealand), and many other oral/non-injectable candidates already in mid-to-late-stage development.
  • Protagonist's primary focus and near-term value drivers are its approved products (ICOTYDE, MIMRYLO) and the more advanced pipeline asset PN-881 (Phase 2b-ready), making PN-458 a very small part of the overall investment thesis.
● neutral
Impact
PhasePreclinical
Time to marketPreclinical stage with no disclosed IND timeline. If development proceeds, clinical trials would likely take several years, meaning potential approval is likely 5+ years away, if at all.

PN-8047 Updated Nov 9

What to watch

PN-8047 has no near-term catalysts. The next meaningful pipeline catalyst for Protagonist is the Phase 2b initiation of PN-881 in early Q1 2027. Watch for any preclinical data disclosures or IND filing announcements for PN-8047 in future earnings calls or scientific conferences, but this program is unlikely to move the stock in the next 12 months.

Bull case
  • PN-8047 is an oral hepcidin mimetic that could be a convenient oral follow-on to MIMRYLO (rusfertide), which is already FDA-approved and generating revenue. An oral version could expand the addressable patient population beyond those willing to take injections.
  • Protagonist has a strong balance sheet ($834.6M cash as of Q3 2026) and a $300M share repurchase program, providing ample funding to advance preclinical programs without financial distress.
  • The company has deep expertise in peptide therapeutics and hepcidin biology, having already brought MIMRYLO through FDA approval, which de-risks the mechanism for PN-8047.
Bear case
  • PN-8047 is at the earliest stage of development (preclinical) with no disclosed IND timeline, no clinical data, and no guarantee it will ever enter human trials.
  • Developing an oral version of a peptide drug is technically challenging; oral bioavailability of peptides is notoriously difficult to achieve.
  • The polycythemia vera market is already served by MIMRYLO (injectable) and other therapies, and an oral hepcidin mimetic would face a long, expensive clinical development path with high attrition risk.

Other drugs in filings and trials

no drug report yet
  • rusfertide Last: Priority review · Mar 2, 2026
  • MIMRYLO Last: NDA filed · Dec 31, 2025

Past FDA events & how the stock moved

7 events
DateDrugEvent1 day5 days
Mar 18, 2026ICOTYDEApproval+4.6%+7.3%
Mar 2, 2026rusfertidePriority review−0.8%+5.0%
Dec 31, 2025MIMRYLONDA filed−0.1%−8.1%
Dec 29, 2025RusfertideNDA filed−1.7%−7.3%
Aug 25, 2025rusfertideBreakthrough designation−0.8%+2.4%
Jul 21, 2025ICOTYDENDA filed−0.9%+1.4%
Jul 1, 2025ICOTYDENDA filed−8.3%−5.4%